In Switzerland, the integration of biosimilars and generics led to savings of approximately 679 million CHF in 2023. However, Switzerland still missed out on potential savings of 90 million CHF due to a continued preference for more expensive original biologics.*
iQone and Celltrion provide a portfolio of cost-effective biosimilars and a strong local support.
* Intergenerika biosimilars report 2023
Our leadership team has decades of experience in the pharmaceutical industry. Having been active in the field for so long, we know what hospitals and physicians are looking for and understand the imperatives of each of the therapeutic areas we address.
Because we recruit only the top experts in their fields, our employees are empowered to take action so as to better serve the healthcare professionals we work with and, ultimately, their patients.